Financial Data and Key Metrics Changes - The company has a strong balance sheet with over $190 million in cash, providing a runway through the first half of 2028 [4][22] - The company has extended its cash runway by a quarter and a half since the transaction with Biogen [6] Business Line Data and Key Metrics Changes - The company has three assets in clinical development: ATI-2138, ATI-45, and ATI-52, with ongoing studies in various indications [3][4] - ATI-45 is in phase three clinical studies in China for severe asthma and CRS with NP, and phase two studies in COPD [4] - A global phase two study in atopic dermatitis has been initiated, with sites in the US, Canada, and Europe [5][14] Market Data and Key Metrics Changes - The pipeline includes highly differentiated large and small molecule assets targeting multibillion-dollar addressable markets [4] - The company is actively seeking partners for ATI-45 in respiratory indications outside of China [14][15] Company Strategy and Development Direction - The company focuses on developing best-in-class therapeutics with a strong emphasis on both large and small molecule drug development [3] - Future plans include reporting top-line data from various studies in 2026, including those for ATI-2138 and ATI-45 [6][7][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical progress and the potential of their pipeline, highlighting a rich catalyst calendar expected in 2026 [6][22] - The company aims to demonstrate the unique pharmacology and safety profile of its assets, particularly in atopic dermatitis and alopecia areata [20][21] Other Important Information - The company has made significant progress in clinical and preclinical plans since the transaction with Biogen [6] - The IND for the bispecific antibody ATI-52 was recently allowed, and phase one SADMAD work has begun [5][17] Q&A Session Summary Question: What are the next steps for the clinical studies? - The company plans to report top-line data from the phase two study of ATI-2138 imminently and initiate a clinical study in alopecia areata [6][20] Question: How does ATI-45 compare to competitors? - Management highlighted that ATI-45 has demonstrated enhanced potency compared to competitors like tezepelumab, with a greater than 60x inhibition of CCL 17 production [9][12] Question: What is the timeline for the next gen ITK selective molecule? - The company plans to file an IND for the next gen ITK molecule in 2026 and begin phase one work shortly thereafter [21][22]

Fourth Quarter and Full Year 2017 Earnings Conference Call February 27, 2018 Agenda | Introduction | Igor Khislavsky | | --- | --- | | | Senior Director, Investor Relations | | Opening Remarks | Jim Taiclet | | | Chairman, President and Chief Executive Officer | | Financial Results | Tom Bartlett | | | Executive Vice President, Chief Financial Officer and | | | Treasurer | Q&A 2 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This presentation c ...

LANVIN GROUP 2023 FULL-YEAR RESULTS April 30, 2024 DISCLAIMER Forward-Looking Statements This presentation ...

August 26, 2024 Forward-Looking Statements This presentation, including the sections "2024 First Half Achievements", "2024 Outlook", "Brand-Level Performance" and "Appendix", contain "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," ...

Financial Performance - Net revenue for the three months ended May 31, 2025, was $7,828 million, a 15.7% increase from $6,765 million for the same period in 2024[117] - Gross profit for the three months ended May 31, 2025, was $681 million, representing 8.7% of net revenue, down from 9.0% in the same period in 2024[128] - Net income attributable to Jabil Inc. for the three months ended May 31, 2025, was $222 million, compared to $129 million for the same period in 2024[117] - Operating income for the three months ended May 31, 2025, was $403 million, up from $261 million in the same period last year, representing a 54% increase[152] - Core operating income (Non-GAAP) for the nine months ended May 31, 2025, was $1,101 million, compared to $1,187 million for the same period in 2024, reflecting a decrease of 7.2%[152] - Adjusted free cash flow (Non-GAAP) for the nine months ended May 31, 2025, was $813 million, an increase from $636 million in the prior year, marking a 27.8% growth[153] Segment Performance - Intelligent Infrastructure segment net revenue increased by 51%, driven by a 40% increase in cloud and data center infrastructure revenues and a 13% increase in capital equipment revenues[125] - The Connected Living and Digital Commerce segment net revenue decreased by 7% due to a 7% decrease in revenues from existing customers[125] - The Regulated Industries segment accounted for 39% of net revenue for the three months ended May 31, 2025, down from 45% in the same period in 2024[127] Expenses and Charges - Selling, general and administrative expenses for the three months ended May 31, 2025, increased to $274 million from $268 million in the same period in 2024[129] - Research and development expenses for the three months ended May 31, 2025, were $7 million, consistent with 0.1% of net revenue, compared to $9 million for the same period in 2024[131] - Amortization of intangibles increased to $17 million for the three months ended May 31, 2025, from $12 million in the same period of 2024, primarily due to acquisitions[132] - Restructuring, severance, and related charges decreased to $16 million for the three months ended May 31, 2025, from $55 million in the same period in 2024[134] - Other expense increased to $30 million for the three months ended May 31, 2025, compared to $22 million in the same period of 2024[144] Cash Flow and Capital Expenditures - Net cash provided by operating activities for the nine months ended May 31, 2025, was $1,052 million, compared to $1,181 million for the same period in 2024[178] - Net cash used in investing activities during the nine months ended May 31, 2025, was $(578) million, primarily due to acquisitions and capital expenditures[180] - The company anticipates net capital expenditures for Fiscal Year 2025 to be in the range of 1.5% to 2.0% of net revenue[182] Acquisitions and Divestitures - The acquisition of Pharmaceutics International, Inc. was completed for a cash consideration of $309 million, enhancing the company's service offerings in regulated industries[155] - The company signed a binding share purchase agreement for the acquisition of Rebound Technologies Group Holdings Limited, a global supply chain service provider, on June 2, 2025[154] - The divestiture of the Mobility Business resulted in a pre-tax gain of $942 million for the fiscal year ended August 31, 2024[163] - The company incurred transaction and disposal costs of approximately $67 million related to the sale of the Mobility Business during the fiscal year ended August 31, 2024[163] Debt and Financing - Total notes payable as of May 31, 2025, amounted to $2,884 million, reflecting a slight increase from $2,880 million as of August 31, 2024[167] - As of May 31, 2025, the company had $4.0 billion in available unused borrowing capacity under existing revolving credit facilities, with $3.2 billion available under the Existing Credit Facility[168] - The company entered into a new senior unsecured credit agreement on June 18, 2025, providing a five-year revolving credit facility of $3.2 billion, potentially increaseable by up to $1.0 billion[169] Share Repurchase and Warrants - The company repurchased 6.5 million shares for $975 million under the 2025 Share Repurchase Program as of May 31, 2025[184] - The company repurchased a total of 2,221,905 shares of common stock during the three months ended May 31, 2025, at an average price of $137.87 per share[196] - The Board of Directors authorized a share repurchase program of up to $1.0 billion in September 2024[196] - The company issued a warrant to Amazon.com NV Investment Holdings LLC for up to 1,158,539 ordinary shares at an initial exercise price of $137.77 per share, with 59,582 shares vested upon issuance[186] - As of May 31, 2025, there are 1,098,957 outstanding warrant shares, with 59,582 exercisable[189] Tax and Other Financial Metrics - Effective income tax rate for the three months ended May 31, 2025, was 23.7%, a decrease of 12.0% from 35.7% in the same period of 2024[148] - Interest expense, net decreased to $112 million for the nine months ended May 31, 2025, from $132 million in the same period of 2024, due to lower interest rates[146] - Loss on securities amounted to $46 million during the three months ended May 31, 2025, related to an impairment of an investment in Preferred Stock[143] Risk Management and Internal Controls - There were no material changes in the company's primary risk exposures or management of market risks since the last annual report[191] - The company did not identify any modifications to its internal control over financial reporting that materially affected its financial reporting for the fiscal quarter ended May 31, 2025[193] - The company’s disclosure controls and procedures were evaluated and deemed effective as of May 31, 2025[192] - The company has no material changes to its contractual obligations and commitments since August 31, 2024[190] - There were no defaults upon senior securities reported during the period[197]

Fourth Quarter and Full Year 2018 Earnings Conference Call February 27, 2019 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements concerning our goals, beliefs, strategies, future operating results and underlying assumptions. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those described in the appen ...

Fourth Quarter and Full Year 2014 Earnings Conference Call February 24, 2015 Agenda | Introduction | Leah Stearns | | --- | --- | | | Senior Vice President, Treasurer and Investor Relations | | Opening Remarks | Jim Taiclet | | | Chairman, President and Chief Executive Officer | | Financial Results | Tom Bartlett | | | Executive Vice President, Chief Financial Officer | | Q&A | | 2 Forward-Looking Statements "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This presentatio ...

Q3 EARNINGS Fiscal 2021 Academy Sports + Outdoors delivered the best third quarter financial results in the Company's history. Q 3 2 0 2 0 $1.60 $2.00 $1.00 $0.00 2 0 1 9 $1.15 $1.35 2 0 21 $1.59 IN BILLIONS Net Sales IN MILLIONS Gross Margin Q 3 2 0 2 0 $400.0 $600.0 $800.0 $200.0 $0.0 $440.5 RATE 32.7% 2 0 1 9 $362.4 RATE 31.6% | $560.8 | RATE | | --- | --- | | 35.2% | | 2 0 21 Comparable Sales Q 3 2 0 2 0 20.0 30.0 10.0 0.0 2 0 1 9 6.2% 2 0 21 17.9% 16.5% This is the ninth consecutive quarter of positive ...

Ares Investor Presentation For Quarter Ended June 30th, 2024 1 Disclaimer The information contained in this presentation is summary information that is intended to be considered in the context of Ares Management Corporation (NYSE: ARES) ("Ares") SEC filings and other public announcements that Ares may make, by press release or otherwise, from time to time. These materials contain information about Ares, its affiliated funds and certain of their respective personnel and affiliates, information about their re ...

Comerica Incorporated February 2025 Investor Presentation Safe Harbor Statement This presentation, & other Comerica written & oral communications, include statements that are not historical facts but rather are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Words such as achieve, anticipate, aspire, assume, believe, can, confident, continue, could, designed, enhances, estimate, expect, feel, forecast, forward, future, goal, grow, guidance, guide, initiative, i ...